Short answer
Spero Therapeutics Inc (SPRO) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics.
Spero Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics
- Press release contains the financial results and management commentary, furnished as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- SP001 Phase 2 IgG4-RD study targeted for Q2 2027, establishing the company’s next major clinical catalyst
- $107.9M cash at September 30, 2026, expected to fund operations into the second half of 2029
- $105M non-dilutive royalty financing supports development while Spero retains 35% of residual Utebzi payments
- Q3 R&D expense $38.2M vs $8.6M, driven primarily by the $35M Innovent upfront licensing payment
- Net loss $44.3M, or $0.76 per share, versus $7.4M, or $0.13 per share, in Q3 2025
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spero Therapeutics Inc 8-K filings
Get the next SPRO 8-K as it lands
Follow SPRO for push alerts, or ask the research agent what this filing means.